e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
New frontiers in the management of interstitial and orphan lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study
Dinesh Khanna (Ann Arbor, United States of America), Dinesh Khanna, Carlo Albera, Aryeh Fischer, James Seibold, Ganesh Raghu, Nader Khalidi, Lorinda Chung, Elena Schiopu, Dan Chen, Eduard Gorina
Source:
International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Session:
New frontiers in the management of interstitial and orphan lung diseases
Session type:
Oral Presentation
Number:
4489
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Dinesh Khanna (Ann Arbor, United States of America), Dinesh Khanna, Carlo Albera, Aryeh Fischer, James Seibold, Ganesh Raghu, Nader Khalidi, Lorinda Chung, Elena Schiopu, Dan Chen, Eduard Gorina. Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study. Eur Respir J 2015; 46: Suppl. 59, 4489
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
High-dose N-acetylcysteine (NAC) in fibrotic interstitial lung diseases, a retrospective analysis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON
Source: International Congress 2016 – IPF treatment II
Year: 2016
Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Pirfenidone post-authorization safety registry (PASSPORT) update
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials
Source: International Congress 2016 – IPF treatment I
Year: 2016
Lymphangioma in patients with pulmonary lymphangioleiomyomatosis – Results of sirolimus treatment
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Effect of baseline statin use on benefit of nintedanib
Source: International Congress 2016 – IPF treatment II
Year: 2016
All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Rituximab therapy for interstitial lung disease in patients with antisynthetase syndrome
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
LATE-BREAKING ABSTRACT: Efficacy of inhaled N-acetylcystein in patients with interstitial pneumonia
Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis
Year: 2014
The efficacy of pirfenidone in scleroderma related interstitial lung disease
Source: Annual Congress 2012 - Diffuse parenchymal lung disease III
Year: 2012
The efficacy of cyclosporine A in patients with clinicoradiologically diagnosed idiopathic nonspecific interstitial pneumonia
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Interstitial lung disease
Source: Eur Respir Rev 2013; 22: 26-32
Year: 2013
Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy
Source: International Congress 2014 – ILDs 4
Year: 2014
Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF treatment II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept